FDA issues vision loss warning for GLP-1 users

The FDA is requiring new warning labels across the GLP-1 drug class about a possible increased risk of a rare eye condition that can cause permanent vision loss. The FDA says the problem is caused by decreased blood flow to the optic nerve and can result in significant loss of vision symptoms including blurry vision and blind spots. Joining us now is Dr. Steve Goldberg, Chief Medical Officer at Healthtrack, to share what this means for consumers.